Skip to main content

Advertisement

Fig. 3 | Genome Medicine

Fig. 3

From: Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies

Fig. 3

Applicability of poly-neoantigen, non-individualized targeted cancer immunotherapies using peptide processing, and MHC-I binding predictions. Top additive “and/or” alterations predicted to produce an MHC-I neoantigen are shown for all tumors (left) and KRAS G12C-driven tumors (right) for two common HLA-A/B subtypes, A*01:01/B*08:01 (top) and A*02:01/B*44:02 (bottom)

Back to article page